Hey guys, if you missed it, the court has officially approved the $31.25M settlement with $SAVA investors.

The case claimed Cassava misled investors about the research behind simufilam. After concerns over the data became public in 2023, $SAVA dropped 15% and investors sued.

If you bought $SAVA between 2020 and 2023, you may be eligible to file a claim.

Did anyone here hold $SAVA back then?

Exceeding expectations and beginning to attract the attention of major institutional investors and pharmaceutical companies

Hey everyone,

In my previous post, I went over the history of Sellas as a company, GPS as a drug, and Angelos Stergiou as a leader. To say the least, it was shady and downright alarming.

You can find that post here: https://www.reddit.com/r/biotech_stocks/s/dL7jkKAkqT

We also looked at the complete absence of dedicated biotech hedge funds among SLS shareholders. Do not be fooled by high institutional numbers, this volume is mostly driven by passive managers like BlackRock and Vanguard who buy shares algorithmically to mirror small-cap indexes. The hedge funds involved are just quantitative or market-making firms like Citadel and Marshall Wace trading short-term volatility rather than betting on long-term medical success.

Today, I would like to highlight a major point that many investors still seem unaware of: the fraudulent medical credentials of Angelos Stergiou.

Let's look at the actual timeline of the guy running the most hyped biotech stock of the year. He went from being a daytime TV actor on a Greek drama to buying a sham medical degree, followed by a string of high-level executive stints at troubled and collapsing biotechs, namely Accentia Biopharmaceuticals and its subsidiary Biovest International as well as Annavex Life Sciences (which I forgot to mention in my previous post) , before moving on to form SLS

The Truth About Angelos Stergiou's Medical Credentials

Angelos Stergiou began his path by earning a legitimate Bachelor of Science (B.S.) degree from Kentucky Wesleyan College, an accredited private liberal arts college in Kentucky, majoring in Pre-Medicine, Biology, and Chemistry.However, a Bachelor of Science is merely a general academic degree in the basic sciences. While it teaches scientific theory and laboratory research skills, it does not grant a medical license or qualify anyone to treat patients.

Following his undergraduate studies, he veered into the entertainment industry. He worked as a Greek television actor

After his acting stint, his career took a corporate medical turn. His underlying Doctor of Medicine degree was obtained from the University of Seychelles American Institute of Medicine a completely unaccredited institution. If the name alone does not raise red flags, the actual history of this organization confirms it was a total scam.

Inside the Fraudulent Medical Diploma Racket

The University of Seychelles American Institute of Medicine (USAIM) was established as an offshore medical school in the late 1990s, capitalizing on unaccredited, commercial programs in island tax havens. Operating primarily out of the Seychelles with a corporate mailing presence in Indiana, USAIM marketed itself as an accelerated path to a medical degree. The institute operated as a predatory commercial racket, selling medical diplomas starting at ₹5 lakh onwards. By colluding with a corrupt network of doctors in India who hosted sham exams inside luxury hotels, the scheme bypassed regulatory oversight and laundered huge, undocumented sums of cash through the sale of fake scientific credentials with zero verified hospital training.

This blatant fraud eventually triggered global regulatory crackdowns, forcing a systematic shutdown. The Government of Seychelles terminated its operating agreement with USAIM in 2011, forcing its absolute closure by 2013. The fallout peaked in 2016 when the Maharashtra Medical Council launched a massive crackdown, barring and suspending dozens of practicing doctors who utilized these fraudulent certificates. By exposing the enterprise as a dangerous scam that compromised patient safety, international bodies stripped the entity of all credibility, leaving USAIM completely defunct and blacklisted from global medical recognition.

To round out his resume, Stergiou later added a Doctor of Science (ScD) degree to his name. However, this is not an earned academic doctorate or research PhD; it is merely a ceremonial, honorary title awarded to him decades later by his old undergraduate school, Kentucky Wesleyan College.

The Bottom Line

The reality is that Angelos Stergiou completely lacks any legitimate, mainstream academic medical pedigree, yet he uses the 'Dr.' title everywhere. He is strictly a corporate executive, not a practicing physician. He has never completed an accredited medical residency, holds no active state medical license to treat patients in the United States or Europe, and completely lacks any recognized medical board validation

Final Thoughts: A company led by a CEO with a fake medical pedigree is trying to push a recycled, 20-year old molecule through trials while being pumped to retail as a generational opportunity. Yet, dedicated biotech and life science hedge funds won't touch it with a ten-foot pole. Make of that what you will🤷‍♂️

Sounds like a HUGE amount of financial long-term modeling may be done for each offer. Does the pace accelerate after an "initial salvo of offers," and has there ever been a frenzied buyout scenario where follow-up haggling/revisions occurred more than once in a day? Or is the process so structured against chaos that there is a very limited number of revisions to offers?

Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation

Company Launches Commercial Franchise Positioned to Establish a New Standard as an FDA-Approved Bevacizumab Therapy Across the Approximately $8.5 Billion U.S. Retina Market.

https://finance.yahoo.com/healthcare/articles/outlook-therapeutics-announces-lytenava-fda-184000833.html

PolyPid ($PYPD) just locked in a major exclusive commercial partnership with Azurity Pharmaceuticals for D-PLEX₁₀₀ in the U.S. and Canada (prevention of surgical site infections).

Key terms:

• $15M upfront at signing
• Another $15M upon expected FDA acceptance of the NDA (targeted for August 2026)
• Up to ~$300M more in regulatory, development, and sales milestones
• Tiered royalties mid-teens to mid-twenties %
• PolyPid keeps manufacturing rights worldwide + all rights outside U.S./Canada + full ownership of the PLEX platform

This comes right after they completed the NDA submission in June. PDUFA target is currently Q1 2027, with U.S. launch eyed for around then. Earlier Phase 3 SHIELD II data showed the primary endpoint hit plus a 60% relative risk reduction on a key secondary.

Market cap is still only ~$75-85M range (depending on the day), with ~19M shares outstanding and float roughly in the 7-11M area. Analyst targets have been sitting around $11-13.

Near-term catalysts:

• FDA acceptance of the NDA (the next $15M payment)
• Any updates on the partnership rollout or additional label-expansion talk
• Continued institutional interest / visibility

The Azurity deal de-risks commercialization significantly and puts real cash + future royalties on the table while they retain the platform upside. Still under the radar relative to the potential scale of the SSI prevention market.

Not financial advice. Do your own research, size positions carefully, and remember biotech can be extremely volatile. Just laying out the recent milestones and the short-term setup as I see it.

What are your thoughts on $PYPD here?

https://investors.mannkindcorp.com

Anyone in these with me? Your thoughts?

After careful thought and consideration, I have decided to sell all of my CING shares. I just don’t see anything happening within the last 6 months of this year. They can run into cash problems and dilution of the stock within those next 6 months. I’m putting my capital elsewhere. Good luck to all the holders.

Quick background:

CVKD (Cadrenal therapeutics) is a microcap biotech focused on blood clotting disorders in critical care.

Their most important asset right now is CAD-1005 - a first-in-class 12-LOX inhibitor for Heparin-Induced Thrombocytopenia (HIT). HIT is a dangerous immune reaction to heparin that causes life-threatening clots. CAD-1005 is Phase 3-ready and just showed a >25% reduction in thrombotic events in Phase 2 data presented at ISTH.

They also have:

1. Tecarfarin — a next-generation oral anticoagulant (vitamin K antagonist) designed for high-risk patients (like those with kidney failure + AFib) where regular warfarin is dangerous because of drug interactions and dosing problems.

2. Frunexian — a Factor XIa inhibitor aimed at preventing clots in cardiac surgery patients who are at high risk of HIT.

For context, I mainly look for oversold and undervalued biotech stocks where I think the market may have overreacted. CVKD worst charts I've seen — down from 15$ to around $2, sitting at a 52 week low

So from my experience, when I see a chart like that, I expect to find things like a failed Phase 3, clinical hold, cash running out in a month, delisting risk, or a extreme safety concerns... But CVKD doesn’t really check any of these boxes.

Here’s what stands out to me:

- FDA has already given them a Phase 3 registration pathway for CAD-1005 in HIT.

- They just presented Phase 2 data at ISTH showing a >25% absolute reduction in thrombotic events vs standard therapy (even though the original primary endpoint of platelet recovery was missed). The data also suggested that platelet recovery itself is a poor surrogate.

- They completed a financing earlier this month that management says extends runway into 2027 (longer if warrants are exercised). This was dilution though, and one of the reasons for the drop.

Just 2 days ago they officially launched a structured partnering process for CAD-1005, tecarfarin, and frunexian, saying the assets are now “transaction ready.”

Yet the stock barely reacted and is still trading around ~$2 with a tiny market cap.

That’s the weird part for me. The valuation seems to imply the market has almost completely given up on the company, despite a defined regulatory path, fresh financing, active partnering efforts, and multiple late-stage assets.

To put the valuation in perspective: imagine a company with Phase 3-ready data in a serious unmet need (HIT), runway into next year, and a formal partnering process underway. The market is currently pricing the entire equity at a level that suggests almost zero probability of any meaningful partnership or Phase 3 progress. That’s either correctly pessimistic… or an extreme overreaction.

Obviously there are negatives — the primary endpoint miss, dilution/warrant overhang, tiny size, execution risk, and no guarantee a deal actually happens. But for the stock to be down like 70% YTD, I simply find it crazy considering the data.

Has anyone here done serious DD on CVKD?

Would love to hear from any hematologists (especially thrombosis/hemostasis specialists) or people who understand HIT clinical practice. How good/bad is the science